tirzepatide and kidney disease Can be used to treat an obese patient with Chronic (CKD) Type 2 Diabetes Mellitus (T2DM), and what is the recommended dose? Tirzepatide Associated with Lower Risk

(Level III) Bohrer J, Chen CC, Falcone T

47 In patients with overweight or obesity without diabetes, the Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) trial showed that tirzepatide 15 mg weekly led to a mean body weight reduction of 20.9% after 72 weeks of treatment, compared with 3.1% with placebo

The FDA will ultimately make the final regulatory decision through a formal rulemaking process, and the agency has gone against advisory panel recommendations before

doi: 10.1056/NEJMoa1411892 116 SalminenPHelmiMOvaskaJJuutiALeivonenMPeromaa-HaavistoPet al

Patel P, Makwana S, Jobanputra U et al (2011) Sublingual route for the systemic delivery of ondansetron

The popular diabetes and weight loss medication semaglutide, known by brand names Ozempic and Wegovy, might offer hope for those struggling to quit smoking